{
    "clinical_study": {
        "@rank": "30016", 
        "arm_group": {
            "arm_group_label": "Cohort"
        }, 
        "brief_summary": {
            "textblock": "This observational study will evaluate the efficacy and safety of Tarceva (erlotinib) in\n      first-line therapy in patients with locally advanced or metastatic EGFR mutation-positive\n      non-small cell lung cancer. Eligible patients, for whom the treating physician has decided\n      to initiate treatment with Tarceva according to the local label will be followed for 18\n      months."
        }, 
        "brief_title": "An Observational Study of Tarceva (Erlotinib) in First Line in Patients With Advanced EGFR Mutation-Positive Non-Small Cell Lung Cancer (GERTAC)", 
        "completion_date": {
            "#text": "August 2013", 
            "@type": "Actual"
        }, 
        "condition": "Non-Small Cell Lung Cancer", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma, Non-Small-Cell Lung", 
                "Lung Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adult patients, >/= 18 years of age\n\n          -  Locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer\n\n          -  Patients for whom the treating physician has decided to initiate first-line therapy\n             with Tarceva in accordance with the Summary of Product Characteristics and local\n             guidelines\n\n        Exclusion Criteria:\n\n          -  N/A"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "Patients with locally advanced or metastatic EGFR mutation positive non-small cell lung\n        cancer"
            }
        }, 
        "enrollment": {
            "#text": "52", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "February 11, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01790217", 
            "org_study_id": "ML27895"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 5, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Oldenburg", 
                    "country": "Germany", 
                    "zip": "26121"
                }
            }
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_groups": "1", 
        "official_title": "GERMAN TARCEVA NON-INTERVENTIONAL STUDY in 1st Line Treatment of NSCLC EGFR Mutation Positive Patients", 
        "overall_official": {
            "affiliation": "Hoffmann-La Roche", 
            "last_name": "Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "August 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Progression-free survival rate at 18 months", 
            "safety_issue": "No", 
            "time_frame": "3.5 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01790217"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Response rate (complete response/partial response) by type of mutation", 
                "safety_issue": "No", 
                "time_frame": "3.5 years"
            }, 
            {
                "measure": "Percentage of patients with remission", 
                "safety_issue": "No", 
                "time_frame": "3.5 years"
            }, 
            {
                "measure": "Progression-free survival (overall/stratified)", 
                "safety_issue": "No", 
                "time_frame": "3.5 years"
            }, 
            {
                "measure": "Overall survival (overall/stratified)", 
                "safety_issue": "No", 
                "time_frame": "3.5 years"
            }, 
            {
                "measure": "Tolerability: Incidence of fatigue, rash, diarrhea", 
                "safety_issue": "No", 
                "time_frame": "3.5 years"
            }, 
            {
                "measure": "Safety: Incidence of serious adverse events", 
                "safety_issue": "No", 
                "time_frame": "3.5 years"
            }, 
            {
                "measure": "Dose modifications/withdrawals", 
                "safety_issue": "No", 
                "time_frame": "3.5 years"
            }, 
            {
                "measure": "Symptom control (cough, dyspnea)", 
                "safety_issue": "No", 
                "time_frame": "3.5 years"
            }
        ], 
        "source": "Hoffmann-La Roche", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hoffmann-La Roche", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2012", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "May 2014"
    }
}